News and stories
Learn more about our work in Peru and the main news of the health sector
A 30 años de su fundación, Socios En Salud repasa los inicios de su trabajo en Perú.
The U.S. National Institutes of Health decided to fund our research focused on the treatment of tuberculosis resistant to the drug isoniazid.
The U.S. National Institutes of Health decided to fund our research focused on the treatment of tuberculosis resistant to the drug isoniazid.
The World Health Organization (WHO) approved three new regimens for multidrug-resistant tuberculosis (MDR-TB) that were studied in the endTB clinical trial that Socios En Salud was part of.
The World Health Organization (WHO) has re-declared an international health emergency due to the outbreak of a new variant of this virus in African countries.
Socios En Salud was present at AIDS 2024, an event where the results of lenacapavir, a highly effective injectable for HIV prevention, were presented.
As part of its RINDE - TB project, Socios En Salud is committed to promoting capacity building in civil society working on tuberculosis, with an outreach in 12 countries in Latin America and the Caribbean.
2023 was a period of achievements and challenges for Socios En Salud. In this review of our activities, we show how our health programs strive each year to bring the cure for injustice everywhere.
Así lo revela el Diagnóstico rápido sobre la situación de estigma y discriminación a mujeres transgénero (MT) en los EESS en 5 regiones del país, realizado en el marco del Proyecto País TB VIH 2022-2025.
Promoting equality, visibility and rights for the LGTBIQ+ community is part of our fight against injustice. We seek to inspire people all over Peru to advocate and take action for health equity and respect for human rights.